MAXVAX Biotechnology Limited Liability Company
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-19
ACTIVE TRIALS5
PHASE 3 / 2-33
RECRUITING1
READOUTS ≤12 MONTHS0
| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| Mid dose Recombinant Trivalent Subunit Rotavirus Vaccine NCT05621655 |
P2 | Active, not recruiting | Rotavirus Infections; Rotavirus Gastroenteritis | 1512 | 2023-04-29 |
| Recombinant Respiratory Syncytial Virus Vaccine (CHO Cells)(low dose) NCT06642558 |
P1/2 | Active, not recruiting | Respiratory Syncytial Virus (RSV) | 522 | 2025-06-30 |
| Recombinant Zoster Vaccine (CHO Cell) NCT06447779 |
P3 | Active, not recruiting | Herpes Zoster | 25000 | 2026-03-29 (+7 mo) |
| Recombinant Respiratory Syncytial Virus Vaccine (CHO Cell) NCT07272434 |
P3 | Recruiting | Respiratory Syncytial Virus (RSV) | 25000 | 2026-07-31 |
| Recombinant Zoster Vaccine (CHO Cell) NCT07293065 |
P3 | Active, not recruiting | Herpes Zoster | 12000 | 2027-12-31 |